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As biomedical technology regarding stem cells moves rapidly ahead, 
new challenges to the existing regulatory frameworks will arise. 
Such a challenge by Regenerative Sciences Inc in the USA recently 
culminated in the filing of a lawsuit by their regulator, the Food and 
Drug Administration (FDA). This lawsuit may last for years. Each 
opposing side bases its case on well-articulated legal values. The 
USA court decision in this case will reverberate worldwide and may 
be cited in future South African constitutional jurisprudence. The 
relevance of each side’s arguments in this matter in the South African 
legal context is evaluated and an outcome ventured should a similar 
case be filed in South Africa today.    
The facts of the matter1
Regenerative Sciences pioneered a stem cell therapy for 
orthopaedic problems, marketed under the trademark ‘Regenexx’. 
It entails harvesting a patient’s own bone marrow or synovial fluid 
surrounding the joints. Stem cells isolated from this tissue are 
grown, processed, mixed with medicinal products outside the body 
and injected back into the patient. Regenerative Sciences claims 
that this assists to regenerate bone and cartilage. They published 
a study involving 227 patients and are submitting another study 
with 339 patients. Both studies show that this novel stem cell-based 
procedure is dramatically safer than the more invasive surgical 
procedures which it helps many patients avoid. However, these 
studies did not include the scientific controls usually expected of 
clinical trials for new medicines.  
Overview of arguments
The FDA’s position is that the autologous stem cell-based substance 
produced using the Regenexx procedure (‘the Regenexx stem cells’) is 
a ‘biological product’ and since therapeutic claims are made about the 
Regenexx stem cells, they also qualify as a ‘drug’ and accordingly fall 
within their regulatory mandate.2 
Regenerative Sciences’ position is that the FDA is acting ultra vires, 
arguing that the FDA’s mandate is to regulate ‘one-on-many’ public health 
risks (e.g. mass production of drugs by a pharmaceutical company), and 
not ‘one-on-one’ doctor-patient medical care risks. As the Regenexx stem 
cells are autologous, therapy amounts to the implantation of the patient’s 
own tissue and falls within the ‘one-on-one’ category. Therefore the FDA 
has no authority to regulate the Regenexx stem cells.3 
Analysis of arguments
Would the Regenexx stem cells be subject to regulation in South 
Africa? 
The nature of the Regenexx stem cells in the South 
African medicolegal context
The legal framework to introduce a new therapeutic substance to the 
South African market is established primarily by the Medicines and 
Related Substances Control Act4 (‘the Medicines Act’). Whether the 
Regenexx stem cells would fit into this legal framework will depend 
on whether they qualify as ‘medicine’ in terms of the Medicines Act – 
‘medicine’ being South Africa’s equivalent legal term for ‘drug’ in the 
USA. If the Regenexx stem cells qualify as medicine, the degree of 
regulation will depend on whether the Regenexx stem cells have been 
called up for registration by a notice in terms of the Medicines Act.
The definition of ‘medicine’ in the Medicines Act is broad: 
‘medicine’ means any substance or mixture of substances used or 
purporting to be suitable for use or manufactured or sold for use in: 
(i) the diagnosis, treatment, mitigation, modification or prevention of 
disease, abnormal physical or mental state or the symptoms thereof in 
man; or (ii) restoring, correcting or modifying any somatic or psychic 
or organic function in man.
It is clear that the Regenexx stem cells would qualify as a medicine 
as they are a substance, have mass and occupy space, and purport to 
be suitable for a therapeutic use. 
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This article attempts to answer the question of whether stem cell 
therapy falls within the current South African regulatory framework, 
using the Regenexx case in the USA as an example. The USA 
regulator, the Federal Drug Administration (FDA), is seeking to 
regulate the Regenexx autologous stem cell therapy as a ‘drug’ and 
a ‘biological product’. The opposing position taken by the inventors 
of the Regenexx therapy is that re-implantation of one’s own body 
parts can in principle not be a ‘drug’ and that the FDA is exceeding 
its mandate. In this article arguments are presented that the Regenexx 
therapy would qualify as a ‘biological medicinal product’ in the South 
African regulatory framework established in terms of the Medicines 
and Related Substances Control Act. As such, the Regenexx therapy 
would be subject to registration with the Medicines Control Council 
(MCC) as a legal precondition for its commercialisation. Furthermore, 
in order to convince the MCC of the safety, efficacy and quality of 
the Regenexx therapy, such therapy must – similar to any other new 
medicine – first be subjected to clinical trials. It is therefore concluded 
that stem cell therapy is indeed comprehensively regulated in South 
Africa, and that a recent opinion expressed in this journal that there 
exists a ‘legislative vacuum’ with relation to the regulation of stem cell 
therapy in South Africa is plainly incorrect.
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More specifically, the Regenexx stem cells would be classified and 
regulated as a ‘biological medicinal product’. The Medicines Control 
Council (MCC), the regulatory body established by the Medicines 
Act, has published guidelines regarding good manufacturing 
practice,5 and guidelines to assist prospective introducers of new 
substances that may qualify as medicines.6 These define ‘biological 
medicinal products’ as including medicines that are ‘derived or 
extracted from biological tissue’.7 Since the Regenexx stem cells are 
derived from a patient’s tissue, they fit the definition neatly. An 
official notice by the MCC states that all medicines that are ‘biological 
products’ (i.e. biological medicinal products) must be registered with 
the MCC and are listed as scheduled substances under Category A, 
Classification 30.8 Thus, the Regenexx stem cells would have to be 
registered with the MCC. 
What about Regenerative Sciences’ ultra vires argument? 
Unlike in the USA, South African law does not distinguish between 
‘one-on-one’ and ‘one-on-many’ risk. The Supreme Court of Appeal 
ruled that to exempt a subsection of the population (in this analysis 
patients who wish to use individualised ‘one-on-one’ stem cell therapy) 
from the provisions of the Medicines Act – even if such subsection 
of the population wants to be exempted! – would undermine the 
purpose of the Medicines Act to protect the entire population and 
therefore cannot be allowed.9 South African courts have consistently 
given a broad interpretation to the MCC’s mandate.10
Does the fact that Regenexx stem cells are human body parts not 
exclude them from qualifying as medicine? As the Medicines Act 
provides no such exclusion, there is no basis for such a mutually 
exclusive alternatives-paradigm. The Regenexx stem cells qualify as 
medicine, irrespective of their characteristics that are irrelevant to 
the definition of ‘medicine’, such as being human body parts or being 
transplanted/implanted. 
Therefore I must conclude that the chances of success of 
Regenerative Sciences’ ultra vires argument would be weak. 
How would the Regenexx procedure be regulated in 
South Africa? 
The effect of the Regenexx stem cells qualifying as registrable 
medicine is that they may only be supplied to a patient if the MCC 
is satisfied with their safety, efficacy and quality and hence grants 
their registration. The MCC may also make registration subject to 
certain conditions. General conditions, such as those regarding good 
manufacturing practice for biological medicinal products, would 
apply to the Regenexx procedure. 
To convince the MCC of the safety, efficacy and quality of a new 
medicine, an applicant will be expected to have conducted well-
constructed and controlled clinical trials.11 The MCC regulates this 
to protect human subjects, and requires prior permission and regular 
reporting. 
A complementary statute that will also affect the Regenexx process 
is the Human Tissue Act.12 Since human tissue is harvested for ‘the 
production of a therapeutic substance’, such harvesting and the 
subsequent isolation of stem cells, cryopreservation and preparation 
of the therapeutic substance are legal. This is subject to provisions, 
including: harvesting must be done by or under supervision of a 
medical practitioner; the patient must give informed consent; and 
the isolation of stem cells, cryopreservation and preparation of the 
therapeutic substance must take place in an authorised institution. 
Conclusion and rectifying the 
perception of a ‘regulatory vacuum’
I conclude that all aspects of the Regenexx process would be legally 
regulated in South Africa, contrary to statements that stem cell 
therapy is in a ‘regulatory vacuum’ in South Africa.13 That paper 
highlights the problem of the proliferation of untested ‘stem cell 
therapies’ around the world and advocates an ethical stance to protect 
the public from potential abuses; any person of conscience must 
agree with this position; and South Africa is sketched as attractive for 
companies looking for a slack stem cell therapy regulatory regimen. 
I strongly differ from this opinion and as indicated, using Regenexx 
as a test case, new stem cell therapies would be subject to the same 
safety, efficacy and quality requirements as any other new medicine. 
The paper states: ‘Chapter 8 of the National Health Act (the major 
part of the legislation in South Africa that deals with the issue of cell-
based therapy) has not been promulgated. This is a serious hiatus, 
since we have to rely on the outdated Human Tissue Act of 1983 to 
provide the necessary legislation.’13 
The reason for the conclusion that there exists a ‘legislative vacuum’ 
in South Africa is the failure to take cognisance of the Medicines Act, 
which is the primary legislation that regulates cell-based therapy, and 
the failure to consider any relevant case law. 
The public must be protected against unethical medical practices. 
However, making the right legal diagnosis is the essential first step 
to addressing social ills and averting the potential proliferation of 
untested ‘stem-cell therapies’.
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